Myrtle Potter
Vant Operating Chair
Roivant Sciences

Myrtle Potter is one of America’s foremost healthcare leaders and innovators. She is Vant Operating Chair at Roivant Sciences, a global biopharmaceutical company that currently has thirty investigational drugs in eleven therapeutic areas being tested in over fifty clinical trials across the Roivant family of companies. She is also founder of Myrtle Potter & Company, LLC, a healthcare and life science advisory firm that has operated since 2005.

Myrtle was president and chief operating officer of Genentech, Inc. where, from 2000 to 2005, she led the company through one of the most successful periods in its history. Genentech achieved record sales and earnings growth during each of the five years she led the company and sales grew more than five-fold to over $5 billion over the same period. Under her leadership the company launched seven breakthrough products including Avastin™, the blockbuster cancer treatment. During her tenure she served on the Executive Committee of the Company and co-chaired the Product Portfolio Committee which made all investment and “go/no go” decisions for Genentech’s drug pipeline.

Prior to Genentech Myrtle was president of Bristol-Myers Squibb’s $4 billion, 3500-person U.S. Cardiovascular and Metabolic business. Under her leadership, this business became the largest, fastest growing and most profitable of all BMS business units. In this role she led the launch of four drugs including the anti-platelet medication Plavix™, making it the fastest growing prescription drug in the industry and setting it on track to be the largest selling prescription drug in the world at that time. She also led the commercialization of Pravachol™ and the Glucophage™ franchise, both multi-billion-dollar businesses. Prior to being named president, she was group vice president of Worldwide Medicines Group where she led a team to successfully reduced BMS R&D cycle time by forty percent.

Myrtle began her biopharmaceutical career at Merck and Company, Inc. where she worked for fourteen years. During her time at Merck she established the new pharmaceutical company, Astra/Merck, Inc. Astra/Merck later merged with Zeneca to form the company AstraZeneca. Following that assignment she directed the marketing of the anti-ulcer medicine Prilosec™ and set it on course to become the largest selling prescription drug in the world at that time, and the first to reach $5 billion in sales. She also managed the commercialization of the anti-ulcer medication Pepcid™ and Merck’s leading portfolio of adult and pediatric vaccines. Her last position at Merck was vice president of an $800 million U.S. pharmaceutical business unit.

Myrtle is an independent director of Rite Aid Corporation, Liberty Mutual Holding Company, Proteus Digital Health, Insmed and Axsome. She also serves on the University of Chicago Board of Trustees. Formerly she served on the boards of Amazon, FoxHollow Technologies, eV3, Medco Health Solutions and Express Scripts

Myrtle was named to FORTUNE Magazine’s list of Most Powerful Women in Business on three separate occasions. Her business and leadership has been recognized by BusinessWeek, The Wall Street Journal, FORTUNE Magazine, TIME Magazine, Forbes, Black Enterprise Magazine, Savoy and Harvard Business Review. Myrtle earned a B.A. from The University of Chicago.